Shanghai Pharma Plans to Use M&A to Expand Overseas

Shanghai Pharma told Bloomberg that it wants to keep doing international deals to expand its portfolio of drug offerings. The company plans to acquire specialty drugs from foreign manufacturers, products that target cancer and cardiovascular disorders, along with branded generics from US or European (especially Switzerland or Germany ) pharmas. It also hopes to acquire foreign manufacturing facilities and to sell its own products in large western markets. The news follows Shanghai Pharma's announcement yesterday that it will acquire Cardinal Health's China drug distribution business for $1.2 billion. More details.... Stock Symbols: (SHA: 600607) (NYSE: CAH) Share this with colleagues: // //